Hims & Hers Reports Q1 Net Loss Amid Shifting Drug Strategy
Hims & Hers Health (NYSE: HIMS) reported a net loss of $92.1 million for the first quarter, down from a profit last year due to shifting away from compounded GLP-1 drugs toward branded alternatives like Wegovy. Despite revenue growth and raised full-year guidance, shares fell over 12% as profitability concerns emerged.
Topics: earnings margins net loss revenue growth telehealth